VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Mumps HN Protein Subunit Vaccine
Vaccine Information
  • Vaccine Ontology ID: VO_0011419
  • Type: Subunit vaccine
  • Status: Research
  • HN gene engineering:
    • Type: Recombinant protein preparation
    • Detailed Gene Information: Click Here.
  • Adjuvant: aluminum hydroxide vaccine adjuvant
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Monkey Response

  • Host Strain: Rhesus macaques
  • Vaccination Protocol: Six monkeys in Group 1 were immunized with 10 μg purified vaccine and adjuvant (aluminum hydroxide, aluminum content: 1.0 mg/ml). Six monkeys in Group 2 were immunized with 20 μg purified vaccine and adjuvant. Two monkeys in Group 3 were immunized with attenuated vaccine (4.1 log CCID50). Two monkeys in Group 4 were mock immunized with 0.9% saline. All experimental groups were immunized by deltoid muscle injection and boosted once per 4-week interval (Liang et al., 2008).
  • Challenge Protocol: Four weeks after the second immunization, all four monkeys in groups of experimental vaccine and all two monkeys in group of attenuated vaccine were challenged with virus, while the others remained uninfected to test their antibody titers at 2, 3, 4 and 6 months after the second dose (Liang et al., 2008).
  • Efficacy: At 1 week after the challenge injection, neutralization antibody was induced in the immunized monkeys to a higher level than in the control monkeys. The clinical and pathological observations after challenge of vaccinated rhesus monkeys indicated further that the immune response induced by this vaccine provided complete protection from wild-type virus infection (Liang et al., 2008).
References
Liang et al., 2008: Liang Y, Ma S, Yang Z, Liu L, Wang L, Wang J, Jiang L, Shi C, Dong C, Li Q. Immunogenicity and safety of a novel formalin-inactivated and alum-adjuvanted candidate subunit vaccine for mumps. Vaccine. 2008; 26(33); 4276-4283. [PubMed: 18597904].